Price History

Hover for the daily close. The dotted line marks the period open.

Compare BLRX with… →

BLRX Key Statistics

As of Sep 4, 2026

Trading

Open: $2.72
Previous Close: $2.69
Day's Range: 2.55–2.72
52-Week Range: 2.15–4.56
Volume: 27.90K
Beta: 0.69

Valuation

Market Cap: $12.95M
P/S ratio: 9.30
EPS (ttm): 0.00

Financials (FY)

Revenue (FY): $1.18M−95.92%
Net Income (FY): −$1.18M
Profit margin: 0.00%
Shares Outstanding: 4.85M
1-Year Return: −24.79%

Dividend and dates

Earnings Date: November 23, 2026estimated
Avg Volume: 20.23K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BLRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+166.10%−86.62%−3.61%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−3.61%
2025	−67.02%
2024	−86.62%
2023	+166.10%
2022	−71.08%
2021	−19.05%
2020	+12.00%
2019	−65.91%
2018	−59.63%
2017	+18.48%
2016 (partial year)	+13.58%

As of September 4, 2026.

BLRX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$1.18M	−$1.18M	−99.6%
2024	$28.94M	−$9.22M	−31.9%
2023	$4.80M	−$60.61M	−1262.8%
2022	$0.00	−$24.95M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$1.18M	$950.00K	−$10.29M	−$1.18M	−99.6%
2024	$28.94M	$19.68M	−$19.15M	−$9.22M	−31.9%
2023	$4.80M	$1.11M	−$42.99M	−$60.61M	−1262.8%
2022	$0.00	$0.00	−$29.16M	−$24.95M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BLRX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	BLRX	Biotechnology median	vs median
P/S ratio	9.30	15.26	39% below
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

BioLineRx Ltd. (BLRX) carries a market capitalisation of $12.95M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 20 employees.

The most recent close on file for BLRX is $2.67, dated September 4, 2026. That is −$0.02 (−0.74%) against the previous close. Over the past 52 weeks the price has ranged from $2.15 to $4.56. The latest close sits 24.19% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.18M. That is −95.92% against the prior fiscal year, when revenue was $28.94M. The same year closed with a net loss of $1.18M. The reported profit margin is 0%. Earnings per share on a trailing basis come to 0.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $1.18M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The price-to-sales ratio is 9.3. On price-to-sales that is 39.06% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −24.79%. Across 10 years the annualized return works out at −40.93%. Beta against the wider market is reported at 0.7. Annualized volatility over the trailing 10 years is 81.66%.

Growth & Income

The record shows no dividend for BLRX.

The strongest complete calendar year on file is 2023 at +166.10%; the weakest is 2024 at −86.62%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the price is −3.61%.

Peer Comparison

BioLineRx Ltd. (BLRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
BioLineRx Ltd.	BLRX	$12.95M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. BioLineRx Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About BioLineRx Ltd.

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Visit website →

BioLineRx Ltd. (BLRX) Stock Analysis